Globe Life, a leading provider of life and health insurance products, was trading at $66.72 when InvestingPro's models flagged the stock as significantly undervalued. The company's strong fundamentals, including consistent premium growth and robust margins, suggested the market was overlooking its true value. At the time, Globe Life reported annual revenue of $5.54 billion and earnings per share of $10.60, with a solid track record of 55 consecutive years of dividend payments. The subsequent performance validated InvestingPro's analysis. Over the following 15 months, Globe Life's stock price surged to $117.60, delivering a 76% return to investors. During this period, the company's fundamentals continued to strengthen, with revenue growing to $5.84 billion and earnings per share reaching $12.36, representing increases of 5.41% and 16.6%, respectively. Recent developments have further supported the investment thesis.